Menu

Former NIH Director James Wyngaarden Dies

The Duke University emeritus professor was an expert in purine biosynthesis and the genetics of gout.

Jun 20, 2019
Jef Akst
OFFICE OF NIH HISTORY AND STETTEN MUSEUM, NATIONAL INSTITUTES OF HEALTH

Former Duke University researcher and administrator James Wyngaarden, who directed the National Institutes of Health from 1982 to 1989, died last week (June 14) at age 94.

“Jim Wyngaarden was a giant among the greatest generation of leaders of American medicine of the 20th Century,” Ralph Snyderman, chancellor emeritus of health affairs at Duke University, says in a statement. “Jim was a creator and model of the physician-scientist, and he had an extraordinary ability to recruit the best people to Duke.”

As chair of the Department of Medicine from the late ’60s until he left to run the NIH in 1982, Wyngaarden recruited, trained, or mentored some three dozen doctors who went on to become medical department chairs, deans, or health system executives themselves, according to the release. After his stint as NIH director, he returned to Duke as associate vice chancellor for health affairs.

Wyngaarden was a world-renowned expert in purine synthesis as well as in the genetics of gout, a complex form of arthritis. Wyngaarden and colleagues discovered that hyperuricemia (too much uric acid in the blood) is a precursor of gout, and that revelation led to the development of a treatment for the condition.

In a letter mourning Wyngaarden’s passing, current NIH Director Francis Collins spoke of his “masterful leadership” during his seven-year run at the agency. “While at the helm of NIH, Dr. Wyngaarden steered the nation’s biomedical research agency through uncharted seas with extraordinary skill,” Collins writes, noting Wyngaarden’s roles in the country’s early research into HIV/AIDS and in the international Human Genome Project. “I am grateful for Dr. Wyngaarden’s selfless dedication to NIH’s mission of turning scientific discovery into health. Whether researcher, health care provider, or patient, we are all benefiting from his wisdom to this day, and will remain forever in his debt.”

October 2019

Brain Fog

Air Pollution May Cause Cognitive Decline

Marketplace

Sponsored Product Updates

Lonza’s MODA-ES™ Platform helps Nephron Pharmaceuticals move from paper to an EBR in nine months - Case study to be presented at 2019 ISPE Annual Meeting 
Lonza’s MODA-ES™ Platform helps Nephron Pharmaceuticals move from paper to an EBR in nine months - Case study to be presented at 2019 ISPE Annual Meeting 
·        Lonza has partnered with Nephron Pharmaceuticals Corporation to implement Lonza’s next-generation MODA-ES™ EBR Platform to streamline manufacturing compliance reporting· The MODA-ES™ Platform was implemented at Nephron in an aggressive nine-month time frame, improving operational efficiency and enabling a significant product line expansion·        Full results of the collaboration will be co-presented by Lonza and Nephron at the 2019 ISPE Annual Meeting & Expo in Las Vegas, Nevada
Understanding T-cell polyfunctionality: How single cell proteomics data drive CAR-T cell therapy research and development
Understanding T-cell polyfunctionality: How single cell proteomics data drive CAR-T cell therapy research and development
Vladimir Senyukov, Director of BioAnalytical Development at Precision Biosciences, talks about investigating T-cell cytokine production using single cell proteomics in order to unlock the therapeutic potential of allogenic CAR-T cells.
Zymo Research launches new RNA-Seq library prep kit
Zymo Research launches new RNA-Seq library prep kit
Zymo Research is excited to announce the fastest and easiest total RNA-Seq library prep kit that allows users to go from sample to sequencer in a single day!